IDH1 and central nervous system cancer: Detection of molecular glioma biomarkers such as MGMT promoter methylation, IDH1/IDH2 mutation, 1p/19q co-deletion, epidermal growth factor receptor (EGFR) amplification and EGFR variant III (EGFRvIII) expression in tumor tissue is increasingly being used in clinical care [64, 70, 183].